Authors’ response: Oxygen therapy in heart failure
Bibliographic record
Abstract
This correspondence refers to ‘Oxygen supplementation in ambulatory patients with heart failure: a randomized proof-of-concept study’, by M. Tremblay-Gravel et al. https://doi.org/10.1093/ehjopen/oeaf074. Authors’ response to the commentary of Kourek and Dimopoulos, https://doi.org/10.1093/ehjopen/oeaf121. We thank Kourek and Dimopoulos for their thoughtful commentary1 on our proof-of-concept study2 evaluating ambulatory oxygen therapy in patients with chronic heart failure (HF). We agree that the methodological and physiological considerations they raise are important, and we welcome the opportunity to clarify several points. First, we acknowledge the concerns regarding potential deleterious haemodynamic effects of hyperoxia. Experimental data suggest that high inspired oxygen concentrations can impair cardiac performance. However, whether these acute physiological changes translate into adverse clinical outcomes in chronic HF remains uncertain, leaving significant equipoise. We also note that the cited pilot work by Dimopoulos et al.3 was conducted in pulmonary arterial hypertension rather than HF, a distinct population in which extrapolation is not straightforward. This adds to the uncertainty and highlights the need for HF-specific evidence. Second, patient heterogeneity is another consideration. While some of our participants had a left ventricular ejection fraction above 40%, our study was not powered for subgroup analyses and its small sample size precludes meaningful segmentation of the population. More importantly, the field of HF is moving beyond a rigid ejection fraction–based framework, as several key therapies, including angiotensin receptor–neprilysin inhibitors, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, have demonstrated benefits across the ejection fraction spectrum.4 All of our study participants shared the same hallmark symptoms of HF, namely, exertional dyspnoea and reduced functional capacity corroborated by elevated N-terminal pro-B-type natriuretic peptide, which were the focus of this exploratory trial. We also agree with the importance of disentangling the cardiac and pulmonary contributions to breathlessness. Although one patient had chronic obstructive pulmonary disease in our study, comorbid pulmonary disease is common in HF, and future studies should carefully characterize pulmonary function with spirometry in all patients. This is particularly relevant given that oxygen therapy has established benefits in chronic obstructive pulmonary disease and related conditions.5 Finally, we concur that in advanced or refractory HF, priorities may shift towards symptom relief even at the expense of potential physiological trade-offs. Patients sometimes place a higher value on quality of life than on longevity, and this perspective should inform the design and goals of future trials.6 It is essential that future clinical trials clearly define whether the aim is to improve HF outcomes or to provide palliative benefit. That said, there is not yet definitive evidence that oxygen therapy confers symptomatic benefit in HF. Our study was small, unblinded, and exploratory, and its results should be considered only as hypothesis-generating. In summary, we emphasize that our findings should not be extrapolated to routine clinical practice at this stage. Rather, they should stimulate the conduct of the larger, rigorous, and well-stratified studies that are needed to explore the role of ambulatory oxygen therapy in HF.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.027 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.004 | 0.003 |
| Scholarly communication | 0.004 | 0.003 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.070 | 0.045 |
| Insufficient payload (model declined to judge) | 0.010 | 0.007 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".